Funding to advance the company’s SMiRNA™ platform to identify clinical candidates in myotonic dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and tauopathies
Boston, September 29, 2021 — Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the close of an $80 million Series B financing. Cormorant Asset Management led the financing with par-ticipation from new investors Westlake Village BioPartners, Surveyor Capital (a Citadel company) and Logos Capital as well as Series A investors RA Capital Management, 5AM, Kleiner Perkins, Sanofi Ventures and Novartis Venture Fund. Proceeds from the financing will be used to advance the company’s small molecule RNA platform (SMIRNA™) to identify clinical candidates in myotonic dys-trophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and various tauopathies.
“Drugging RNA with small molecules has the potential to dramatically transform the lives of pa-tients and we are excited to be supported by world-class investors who share our commitment to patients and our vision to develop innovative therapies to treat severe RNA-mediated diseases, in-cluding neurodegenerative and neurological disorders,” said Renato Skerlj, Ph.D., President and Chief Executive Officer of Expansion Therapeutics. “This financing milestone demonstrates signifi-cant investor confidence in the leadership team, the science and our mission to accelerate the preclinical and clinical development of our novel medicines utilizing our proprietary approach.”
Expansion focuses on structured RNA targets that are evolutionarily conserved or genetically demonstrated to cause disease. Disease-driving RNA structures amenable to ligand binding are identified by combining patient genetics with deep informatic analysis and then screened against Expansion’s proprietary RNA-focused libraries for small molecules that modulate the RNA target in a functionally relevant manner. Expansion’s novel structural biology SMiRNATM platform is then uti-lized for the design and advancement of lead-like chemical matter that ultimately delivers an oral medicine to treat disease. Expansion is focused on neurological diseases where few treatment op-tions are available for patients such as myotonic dystrophy type 1 which is a system wide disorder affecting muscle, cardiac and brain function. A small molecule medicine that treats all aspects of the disease offers patients a significant benefit.
“Recent advances in understanding RNA structure and the science of targeting RNA with small mol-ecules offer tremendous opportunities to transform the way RNA-mediated diseases are treat-ed. We believe Expansion’s established focus on structured RNA targets position them as leaders in this emerging space,” said Andy Phillips, Ph.D., Managing Director at Cormorant. “We’re extremely enthusiastic about the promise that the SMiRNATM platform holds to deliver disease-modifying therapies for a wide range of devastating neurological disorders, particularly neurodegenerative diseases,” added Raymond J. Kelleher, M.D., Ph.D., also Managing Director at Cormorant.
“The progression of Expansion’s lead programs, broad therapeutic potential of the platform, and the leadership team’s demonstrated track record in the field of neuroscience compelled us to partner with this exceptionally strong group of drug developers, as well as Cormorant and the rest of the investor syndicate,” said Andrew Levine, M.D., Ph.D., Managing Director at RA Capital Man-agement. “We are confident in Expansion’s ability to leverage its differentiated platform to posi-tively impact the lives of patients suffering from severe and debilitating neurological diseases who currently have limited or no treatment options,” added Laura Tadvalkar Ph.D., Principal at RA Capi-tal Management.
As part of its initiative to broaden its portfolio of small molecule medicines, Expansion also recently in-licensed two new research programs from Scripps Research, including a program targeting tau, an important driver of dementia disorders. The tau program builds on the observation that defec-tive pre-mRNA encoding the production of tau protein is involved in the formation of neurofibrilla-ry tangles and has been linked to tauopathies such as Alzheimer’s disease, frontotemporal demen-tias, progressive supranuclear palsy and other neurodegenerative diseases.
About Expansion Therapeutics
Expansion Therapeutics is a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases including neurodegenerative disorders. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule RNA modulators. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of severe RNA-mediated disease indications. Headquartered in Boston, Massachusetts, Expansion’s research facility is located in Jupiter, Florida. For more information, visit www.expansionrx.com.
Sam Brown Inc.